Chlorosulfonyl N-tert-butylcarbamate

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Chlorosulfonyl N-tert-butylcarbamate
• 英文别名: chlorosulfonyl N-tert-butylcarbamate
• 化学式: C₅H₁₀ClNO₄S
• 分子量: 215.66
• InChiKey: KTOCCOVRPVBVMJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  80.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Sulfamate derivative compounds, processes for preparing them and their uses
  申请人：BIO-PHARM SOLUTIONS CO., LTD.

  公开号：US10351519B2

  公开（公告）日：2019-07-16

  The present invention relates to a pharmaceutical composition for treating or preventing CNS disorders containing a sulfamate derivative compound and/or pharmaceutically acceptable salt thereof as an active ingredient. Furthermore, the present invention relates to a method for treatment or prevention CNS disorders comprising administering a sulfamate derivative compound in a pharmaceutically effective amount to a subject in need of treatment or prevention of CNS disorders.

  本发明涉及一种用于治疗或预防中枢神经系统疾病的药物组合物，其中含有一种氨基磺酸衍生物化合物和/或其药学上可接受的盐作为活性成分。此外，本发明还涉及一种治疗或预防中枢神经系统疾病的方法，该方法包括向需要治疗或预防中枢神经系统疾病的受试者施用药学有效量的氨基磺酸酯衍生物化合物。
• Sultam compound and application method thereof
  申请人：Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  公开号：US11111240B2

  公开（公告）日：2021-09-07

  Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method thereof, and a pharmaceutical composition containing the compound. The compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition containing the compound can be used to treat IDH1 mutation-induced cancers.

  本发明提供了一种由式 I 表示的具有异柠檬酸脱氢酶 1（IDH1）抑制活性的舒坦化合物或其药学上可接受的盐、溶液或水合物、其制备方法以及含有该化合物的药物组合物。该化合物或其药学上可接受的盐、溶液或水合物以及含有该化合物的药物组合物可用于治疗 IDH1 突变诱导的癌症。
• SULTAM COMPOUND AND APPLICATION METHOD THEREOF
  申请人：Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  公开号：EP3434671B1

  公开（公告）日：2020-10-21
• SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES
  申请人：Bio-Pharm Solutions Co., Ltd.

  公开号：EP3423433A1

  公开（公告）日：2019-01-09
• Sultam Compound And Application Method Thereof
  申请人：Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  公开号：US20210047314A1

  公开（公告）日：2021-02-18

  Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method thereof, and a pharmaceutical composition containing the compound. The compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition containing the compound can be used to treat IDH1 mutation-induced cancers.